Home › Compare › BRCOQ vs ABBV
BRCOQ yields 2000000.00% · ABBV yields 3.06%● Live data
📍 BRCOQ pulled ahead of the other in Year 1
Combined, BRCOQ + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BRCOQ + ABBV for your $10,000?
The Beard Company, through its subsidiaries, engages in carbon dioxide, oil and gas, coal reclamation, and e-commerce businesses in the United States. The company's Carbon Dioxide segment produces and sells carbon dioxide gas in Colorado and New Mexico. Its Oil and Gas segment engages in the exploration, development, production, and sale of oil and gas. This segment owns non-operated working interests or overriding royalty interests in producing wells in Colorado and Wyoming; and undeveloped oil and gas leases in such states and in Mississippi. The company's Coal Reclamation segment operates coal fines reclamation facilities; and provides slurry pond core drilling services, fine coal laboratory analytical services, and consulting services. Its e-Commerce segment holds Voucher patent that is offered under royalty basis. The company was founded in 1921 and is headquartered in Oklahoma City, Oklahoma. On October 12, 2012, The Beard Company, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Western District of Oklahoma. Beard Co. is in liquidation.
Full BRCOQ Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.